Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... in clinical trials improving atopic dermatitis (AD) in moderate-to-severe patients, where it is the first systemic ...
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback